Lipid Nanoparticles Decorated with TNF-Related Aptosis-Inducing Ligand (TRAIL) Are More Cytotoxic than Soluble Recombinant TRAIL in Sarcoma

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer

(2016) Diego De Miguel et al.   CANCER LETTERS

Onto better TRAILs for cancer treatment

(2016) D de Miguel et al.   CELL DEATH AND DIFFERENTIATION

TRAIL-coated lipid-nanoparticles overcome resistance to soluble recombinant TRAIL in non-small cell lung cancer cells

(2016) Diego De Miguel et al.   NANOTECHNOLOGY

Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells

(2016) Diego De Miguel et al.   Recent Patents on Anti-Cancer Drug Discovery

Evaluation of the safety and efficacy of TRAIL and taurolidine use on human fibrosarcoma xenografts in vivo

(2016) KAMRAN HARATI et al.   Oncology Letters

Immunotherapy with liposome-bound TRAIL overcomes partial protection to soluble TRAIL-induced apoptosis offered by down-regulation of Bim in leukemic cells

(2015) D. De Miguel et al.   Clinical & Translational Oncology

Targeting TRAIL in the treatment of cancer: new developments

(2015) Bora Lim et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Liposome-bound TRAIL induces superior DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells

(2015) Diego De Miguel et al.   LEUKEMIA RESEARCH

Getting TRAIL back on track for cancer therapy

(2014) J Lemke et al.   CELL DEATH AND DIFFERENTIATION

Proteasome inhibitor MG132 enhances TRAIL-induced apoptosis and inhibits invasion of human osteosarcoma OS732 cells

(2013) Xiucheng Li et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Death receptors as targets in cancer

(2013) O Micheau et al.   BRITISH JOURNAL OF PHARMACOLOGY

Death receptor agonist therapies for cancer, which is the right TRAIL?

(2013) Pamela M. Holland   CYTOKINE & GROWTH FACTOR REVIEWS

Effects of TRAIL and taurolidine on apoptosis and proliferation in human rhabdomyosarcoma, leiomyosarcoma and epithelioid cell sarcoma

(2013) C. KARLISCH et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Liposomes Decorated with Apo2L/TRAIL Overcome Chemoresistance of Human Hematologic Tumor Cells

(2013) Diego De Miguel et al.   MOLECULAR PHARMACEUTICS

Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer

(2012) Luis Martinez-Lostao et al.   BIOCHEMICAL PHARMACOLOGY

The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial

(2012) J. J. Luke et al.   CLINICAL CANCER RESEARCH

State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL

(2012) Stella Bernardi et al.   Recent Patents on Anti-Cancer Drug Discovery

FLIPLinduces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity

(2011) Cristina Pop et al.   BIOCHEMICAL JOURNAL

Engineering death receptor ligands for cancer therapy

(2011) Harald Wajant et al.   CANCER LETTERS

cIAPs Block Ripoptosome Formation, a RIP1/Caspase-8 Containing Intracellular Cell Death Complex Differentially Regulated by cFLIP Isoforms

(2011) Maria Feoktistova et al.   MOLECULAR CELL

Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis

(2010) Luis Martinez-Lostao et al.   ARTHRITIS AND RHEUMATISM

Proteasome inhibitor Bortezomib induces cell-cycle arrest and apoptosis in cell lines derived from Ewing’s sarcoma family of tumors and synergizes with TRAIL

(2010) Guangrong Lu et al.   CANCER BIOLOGY & THERAPY

TRAIL and Doxorubicin Combination Induces Proapoptotic and Antiangiogenic Effects in Soft Tissue Sarcoma In vivo

(2010) S. Wang et al.   CLINICAL CANCER RESEARCH

A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors

(2010) Mark Andrew Dickson et al.   INVESTIGATIONAL NEW DRUGS

Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis

(2008) Patricia Balsas et al.   BIOCHEMICAL PHARMACOLOGY

Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonist Antibody

(2008) A. Shanker et al.   JNCI-Journal of the National Cancer Institute